The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26% and 15% as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.
|Translated title of the contribution||Results obtained by intravesical instillation of BCG in superficial bladder tumors|
|Number of pages||4|
|Publication status||Published - Jan 7 1990|
ASJC Scopus subject areas